Multi-organ system and quality-of-life benefits sustained through three and a half years 86% response rate for the multi-component endpoint 89% ...

(UroToday.com) The 2026 ASCO annual meeting featured an optimizing care for patients with metastatic castration resistant prostate cancer (mCRPC) session and a presentation by Dr. Karim Fizazi ...

Multi-organ system and quality-of-life benefits sustained through five years of treatment– 82% response rate for the multi-component endpoint – ...

Experts discuss the evolution of AI in pain medicine and its role in clinical decision support and personalized care models.

Multi-organ system and quality-of-life benefits sustained through five years of treatment - 82% response rate for the multi-component endpoint - 95% of patients completed five years of treatment COPEN ...